|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
CTG00572676X |
003 |
DE-627 |
005 |
20230425164923.0 |
007 |
cr uuu---uuuuu |
008 |
210507s2021 xx |||||o 00| ||eng c |
035 |
|
|
|a (DE-627)CTG00572676X
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2020-001936-86-DE
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)COMET
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
245 |
1 |
0 |
|a Clinical trial to evaluate superiority of anti-SARS-CoV-2 convalescent plasma versus standard-of-care in hospitalized patients with mild COVID-19
|b A prospective, randomized, open label Phase 2 clinical trial to evaluate superiority of anti-SARS-CoV-2 convalescent plasma versus standard-of-care in hospitalized patients with mild COVID-19 - Convalescent Plasma in Mild Covid-19 for Early Treatment
|
264 |
|
1 |
|c 2021
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 20-08-2020, Last updated: 2022-11-24
|
650 |
|
4 |
|a Medical Condition: Hospitalized patients with mild SARS-CoV-2 infection (WHO R&D Blueprint Ordinal Scale for Clinical Improvement = 3 or 4) MedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Virus Diseases [C02]
|
650 |
|
4 |
|a Study Type: Interventional
|
650 |
|
4 |
|a Phase: Phase 2
|
650 |
|
4 |
|a Recruitment Status: Not yet recruiting
|
650 |
|
4 |
|a 610
|
773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2021) vom: 06. Dez.
|
773 |
1 |
8 |
|g year:2021
|g day:06
|g month:12
|
856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001936-86
|z kostenfrei
|3 Volltext
|
912 |
|
|
|a GBV_CTG
|
912 |
|
|
|a SSG-OLC-PHA
|
951 |
|
|
|a AR
|
952 |
|
|
|j 2021
|b 06
|c 12
|